Cantor Fitzgerald reiterates Rocket Lab stock rating on strong revenue By Investing.com

Rocket Lab reported first-quarter fiscal 2026 revenue of $200.3 million, its highest quarterly revenue on record and above the $190.9 million consensus estimate, with sales up 63.5% year over year. Cantor Fitzgerald reiterated an Overweight rating and raised its price target to $96, while management said the Neutron rocket remains on track for first launch later this year. The company has completed 87 successful launches and continues to see launch heritage and customer diversification as key competitive advantages.

Analysis

The core signal is not just that the name is gaining credibility; it is that the market is starting to re-rate Rocket Lab from a “single-program launch story” into a multi-revenue-platform defense/infrastructure compounder. That transition matters because the first leg of valuation expansion usually comes from the market assigning higher probability to recurring government-adjacent demand and to higher-multiple systems revenue, not from launch cadence alone. If that shift sticks, the stock can keep working even if launch counts are flat, because the mix matters more than the headline throughput.

Second-order, the real competitive pressure lands on smaller launch peers and on any supplier ecosystem exposed to a delayed Neutron timeline. A credible medium-lift path increases Rocket Lab’s bargaining power with payload customers who otherwise would split launches across fragmented providers, and it can compress the value of “launch-only” rivals that lack integrated systems, manufacturing, and a visible U.S./non-U.S. footprint. The most important hidden driver is not the next launch, but whether the company can convert its backlog and heritage into multi-year customer lock-in before larger launch incumbents fully scale their own offerings.

The risk is classic duration risk: the equity is likely discounting a sequence of good outcomes over the next 6-12 months, so any schedule slip, margin miss, or guidance conservatism can hit harder than the operational issue itself. The setup is also vulnerable to “sell the news” around headline milestones, especially if broader growth-tech de-rates ahead of major semiconductor earnings and squeezes speculative factor exposure. In other words, near-term upside is tied to confirmation, while downside could come from any evidence that the path to Neutron monetization is longer than the market is pricing.

The contrarian view is that the market may be overpaying for optionality that is still several execution steps away from cash flow durability. If the current multiple is already discounting a successful Neutron launch and sustained execution, then the better risk/reward may be in expressing the view through options or relative value rather than outright long stock. The stock can still go higher, but the path likely depends on multiple expansion first and fundamental earnings power later.

Key Decisions for Investors

• Long RKLB into confirmation windows over the next 1-3 months, but size modestly; use a stop on any material launch-timeline slippage because the stock is trading on execution credibility rather than current cash flow.
• Prefer RKLB call spreads 3-6 months out over outright common stock to capture re-rating upside while defining downside if sentiment fades after the next catalyst.
• Pair trade: long RKLB / short a launch-only or pre-profitability aerospace peer over the next 6-12 months to express the view that integrated systems + launch heritage deserves a premium over single-product models.
• If already long, trim strength after catalyst-driven spikes and re-add on post-event pullbacks of 8-12%; the setup is vulnerable to “sell the news” behavior in high-beta thematic names.
• For defensive exposure, hedge RKLB with short-duration tech-beta or speculative growth basket shorts ahead of major market risk events; the stock’s factor sensitivity can overwhelm company-specific positives in a risk-off tape.